Response to pemetrexed chemotherapy in lung adenocarcinoma- bronchioloalveolar carcinoma insensitive to erlotinib

Clinical Lung Cancer

Volumn 11, Issue 1, 2010, Pages 57-60

  Manson, Greg V ^a   Ma, Patrick C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Carboplatin; Cisplatin; Lymphadenopathy; Non small cell lung cancer; Paclitaxel; Single agent therapy

Indexed keywords

CARBOPLATIN; ERLOTINIB; PACLITAXEL; PEMETREXED;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG LOBECTOMY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; TREATMENT RESPONSE;

EID: 77249133298     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.009     Document Type: Article

References (30)

1. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7:169-181
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
3. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-595
4. National Cancer Institute [Web site]. Phase III randomized study of pemetrexed disodium versus erlotinib hydrochloride as second-line therapy in patients with advanced non-small cell lung cancer. Available at: http://www.cancer.gov/clinicaltrials/NCCTG-N0723. Accessed: November 23, 2009.
5. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-smallcell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792 (Pubitemid 40271173)
6. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
7. Booth CM, Shepherd FA. Adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2006; 1:180-187
8. Strauss GM, Herndon JE, 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043-5045
9. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY23 1514 (MTA). Adv Enzyme Regul 1998; 38:135-152
10. Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 2006; 26:641-654
11. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3545
12. Gomez HL, Santillana SL, Vallejos CS, et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12:832-838
13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
14. Clinicaltrials.gov [Web site]. First line IRESSA™ versus carboplatin/paclitaxel in Asia (IPASS). Available at: http://clinicaltrials.gov/ ct2/show/NCT00322452?term=NCT00322452&rank=1. Accessed: November 23, 2009.
15. West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24:1807-1813
16. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26:1472-1478
17. Kris MG, Giaccone G, Davies A, et al. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol 2006; 1:S32-6.
18. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23:857-865
19. Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008; 113:3199-3208
20. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096
21. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-20937
22. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 3:1039-1043
23. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009; 20:298-304.
24. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factorIR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13:2795-2803
25. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004; 10:4276s-80s.
26. Wong KK, Fracasso PM, Bukowski RM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009; 15:2552-2558
27. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF234 1066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67:4408-4417
28. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-4368
29. Davies AM, Ho C, Beckett L, et al. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thoracic Oncol 2009; 4:862-868
30. Clinicaltrials.gov [Web site]. Pemetrexed disodium with or without erlotinib in treating patients with stage IIIB or stage IV non-small cell lung cancer that responded to previous erlotinib. Available at: http:// clinicaltrials.gov/ct2/show/NCT00660816. Accessed: November 23, 2009.